Novobiotic Pharmaceuticals, LLC

Northeastern University

Tufts University

The General Hospital Corporation

Holobiome, Inc.

Massachusetts Institute of Technology

Exxon Research and Engineering Company

Kim Lewis

Slava Epstein

Aaron J Peoples

Dallas E Hughes

Losee Lucy Ling

Anthony Nitti

William Millett

Amy Spoering

Linos Lazarides

Victoria Alexandra Steadman

Jean-Yves Christophe Chiva

Michael Kenyon Jones

Karine Gaelle Poullennec

Frederick M Ausubel

Anthony D'onofrio

Kelly Demeo

Akira Iinishi

Peichun Hsieh

Ashley Zullo

Philip Strandwitz

Terence I Moy

Alysha Desrosiers

Catherine Achorn

Alexander M Klibanov

Chun-Jen Liao

Charles Moore

Catherine L Coyle

Suresh Gopalan

Matthew J Grossman

Michael S Logan

Gerben Zylstra

Read Pukkila-Worley

Charlotte Berkes

Thomas Curtis

Yu Imai

Xiaoqian (Wendy) Wu

Anthony Ferrante

Alexander A Klibanov

Nadja Leimer

Mithra Rothfeder

Kirsten Meyer

Quentin Favre-Godal

Tammi Kaeberlein

Joerg C Tiller

Lucy Ling

Qibo Zhang

Annie Conery

Ekaterina Gavrish

Slava S Epstein

Dallas Hughes

The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.

Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system

Assays for compounds having a desired biological activity against one but not both of a pair of microorganism species utilize separately detectable labels. The first and second microorganisms are different from each other, the first microorganisms exhibit a first detectable label, the second microorganisms exhibit a second detectable label different from the first detectable label, and neither of the labels interferes with detection of the other label. In various embodiments, the first and second microorganisms are incubated with a candidate compound or a producer thereof. The different labels permit isolation of microorganisms exhibiting one of the labels but not the other, indicating the desired activity, and the compound responsible for this differential response is isolated.

Selectivity screening for antimicrobial compounds

This invention provides, among other things, compounds useful for treating spirochete diseases such as Lyme disease, as well as pharmaceutical formulations and/or environmental baits containing such compounds.

Hygromycin a compounds and methods of treating spirochete diseases

The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Depsipeptides and uses thereof

The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

Depsipeptide and uses thereof

Embodiments of the present invention relate to a novel compound of Formula (I) or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria. 

Isolated darobactin A analog compounds and compositions thereof

Methods for producing a depsipeptide

The invention features compounds that have antibacterial activity, their use for the treatment of bacterial infections, screening methods that use whole animals or plant seedlings to identify compounds that inhibit a pathogen in the animal or plant, and screening methods to identify compounds that increase the lifespan of an organism.

Methods for screening antimicrobial and antiviral compounds and uses thereof

Devices and methods for isolating and/or culturing microorganisms are provided. The devices comprise one or more semi-permeable membranes and may additionally include a growth medium for the microorganism. The devices and methods described herein can be used to isolate and culture both known and novel microorganisms from any environment.

Devices and methods for the selective isolation of microorganisms

This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections.

Antimicrobial compounds

Growing community of inventors

Newton, MA, United States of America

Kim Lewis